GlassScriptPhysician profile
Weston Scott Stover
NPI 1366837353
$566.39
in general payments reported to CMS, 2019-2025
15 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.12 · 2023: $243 · 2024: $157 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $100.59 | 2023 | Imfinzi, Tagrisso, Lynparza |
| Hologic Sales and Service, LLC | $74.95 | 2025 | Coolseal Generator, Magtrace |
| Medtronic, INC. | $72.48 | 2023-2025 | Signia, Ligasure |
| Smith+Nephew, INC. | $46.04 | 2024 | Stravix Pl |
| W. L. Gore & Associates, INC. | $43.59 | 2023 | Gore Bio-A Tissue Reinforcement |
| Boston Scientific Corporation | $38.85 | 2024-2025 | Spyglass Discover |
| Daiichi Sankyo INC. | $29.48 | 2024 | Enhertu |
| Karl Storz Endoscopy-America | $26.75 | 2025 | Na |
| E.R. Squibb & Sons, L.L.C. | $24.30 | 2024 | Opdivo |
| Merck Sharp & Dohme LLC | $23.81 | 2024 | Zerbaxa |
| Celgene Corporation | $21.51 | 2023 | Opdualag |
| Avanos Medical | $18.12 | 2023 | On-Q* Pump and Accessories |
| Incyte Corporation | $15.83 | 2023 | Pemazyre, Monjuvi |
| Aveo Pharmaceuticals, INC. | $15.12 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $14.97 | 2024 | Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weston Stover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.